VANCOUVER and MINNEAPOLIS, May 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire ‒ Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the first patient has been enrolled in the COronary SInus Reducer for the Treatment of Refractory Microvascular Angina (“COSIMA”) trial. The enrollment occurred at University […]